These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 31936266

  • 1. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC, Koch B, Freitag J, Schubert R, Geiger H.
    Int J Mol Sci; 2020 Jan 08; 21(2):. PubMed ID: 31936266
    [Abstract] [Full Text] [Related]

  • 2. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
    Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A.
    PLoS One; 2013 Jan 08; 8(2):e54442. PubMed ID: 23390498
    [Abstract] [Full Text] [Related]

  • 3. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG.
    Cardiovasc Diabetol; 2018 Jul 30; 17(1):108. PubMed ID: 30060748
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H.
    PLoS One; 2014 Jul 30; 9(6):e100777. PubMed ID: 24960177
    [Abstract] [Full Text] [Related]

  • 7. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway.
    Yao D, Wang S, Wang M, Lu W.
    Mol Med Rep; 2018 Oct 30; 18(4):3625-3630. PubMed ID: 30132524
    [Abstract] [Full Text] [Related]

  • 8. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S.
    Horm Metab Res; 2015 Aug 30; 47(9):686-92. PubMed ID: 25611208
    [Abstract] [Full Text] [Related]

  • 9. Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro.
    Koch B, Fuhrmann DC, Schubert R, Geiger H, Speer T, Baer PC.
    Int J Mol Sci; 2023 Jan 17; 24(3):. PubMed ID: 36768138
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells.
    Zaibi N, Li P, Xu SZ.
    PLoS One; 2021 Jan 17; 16(2):e0247234. PubMed ID: 33606763
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney.
    Hodrea J, Balogh DB, Hosszu A, Lenart L, Besztercei B, Koszegi S, Sparding N, Genovese F, Wagner LJ, Szabo AJ, Fekete A.
    Am J Physiol Renal Physiol; 2020 Apr 01; 318(4):F1017-F1029. PubMed ID: 32116017
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Empagliflozin in the elderly].
    Berrut G, Boureau AS, Trochu JN, Genet B, de Decker L, Hanon O.
    Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun 01; 19(2):137-147. PubMed ID: 34165436
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y, Breljak D, Onishi A, Batz F, Patel R, Huang W, Song P, Freeman B, Mayoux E, Koepsell H, Anzai N, Nigam SK, Sabolic I, Vallon V.
    Am J Physiol Renal Physiol; 2018 Aug 01; 315(2):F386-F394. PubMed ID: 29412698
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
    Elkazzaz SK, Khodeer DM, El Fayoumi HM, Moustafa YM.
    Life Sci; 2021 Sep 01; 280():119018. PubMed ID: 33549594
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.